StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.68+0.16 (+0.23%)

Close on Nov 17, 2026Market cap $39.49BP/E 39.0Yield –

Royalty Pharma operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Royalty Pharma's operating cash flow for the twelve months ending Jun 30, 2026 was $2.98B, up 23.7% year over year. For fiscal 2025 it was $2.49B, down 10.1% from the year before. The highest annual figure on record is $2.99B in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.49B-10.1%
FY2024Dec 31, 2024$2.77B-7.3%
FY2023Dec 31, 2023$2.99B+39.4%
FY2022Dec 31, 2022$2.14B+6.3%
FY2021Dec 31, 2021$2.02B-0.8%
FY2020Dec 31, 2020$2.03B+22.0%
FY2019Dec 31, 2019$1.67B+3.0%
FY2018Dec 31, 2018$1.62B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$728.46M+100.1%
Q1 FY2026Mar 31, 2026$718.23M+20.5%
Q4 FY2025Dec 31, 2025$827.15M+11.4%
Q3 FY2025Sep 30, 2025$702.62M-0.1%
Q2 FY2025Jun 30, 2025$363.98M-44.7%
Q1 FY2025Mar 31, 2025$596.08M-10.3%
Q4 FY2024Dec 31, 2024$742.53M-3.9%
Q3 FY2024Sep 30, 2024$703.61M+22.7%
Q2 FY2024Jun 30, 2024$658.21M+8.3%
Q1 FY2024Mar 31, 2024$664.64M-35.7%
Q4 FY2023Dec 31, 2023$772.63M+35.6%
Q3 FY2023Sep 30, 2023$573.52M+6.4%
Q2 FY2023Jun 30, 2023$607.82M+5.7%
Q1 FY2023Mar 31, 2023$1.03B+124.6%
Q4 FY2022Dec 31, 2022$569.93M+16.3%
Q3 FY2022Sep 30, 2022$538.83M+14.7%
Q2 FY2022Jun 30, 2022$574.95M+8.1%
Q1 FY2022Mar 31, 2022$460.27M-12.5%
Q4 FY2021Dec 31, 2021$489.96M-13.4%
Q3 FY2021Sep 30, 2021$469.76M-7.7%
Q2 FY2021Jun 30, 2021$531.72M+8.7%
Q1 FY2021Mar 31, 2021$526.10M+11.7%
Q4 FY2020Dec 31, 2020$565.67M+18.2%
Q3 FY2020Sep 30, 2020$508.85M+21.4%
Q2 FY2020Jun 30, 2020$489.00M–
Q1 FY2020Mar 31, 2020$471.10M–
Q4 FY2019Dec 31, 2019$478.43M–
Q3 FY2019Sep 30, 2019$419.03M–

More Royalty Pharma figures

See a number that looks wrong?